Drug efflux transporters and multidrug resistance in acute leukemia: Therapeutic impact and novel approaches to mediation

Molecular Pharmacology

Volumn 82, Issue 6, 2012, Pages 1008-1021

  Xia, Cindy Q ^a   Smith, Peter G ^a,b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CANCER PROGNOSIS; DNA POLYMORPHISM; GENE OVEREXPRESSION; HUMAN; LEUKEMIA REMISSION; MULTIDRUG RESISTANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; UPREGULATION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; P-GLYCOPROTEINS;

EID: 84869804156     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079129     Document Type: Short Survey

References (211)

1. Abbasi M, Aliabadi HM, Moase EH, Lavasanifar A, Kaur K, Lai R, Doillon C, and Uludaǧ H (2011a) siRNA-mediated down-regulation of P-glycoprotein in a xenograft tumor model in NOD-SCID mice. Pharm Res 28:2516-2529.
2. Abbasi M, Lavasanifar A, and Uluda H (2011b) Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer. Med Res Rev doi:10.1002/med.20244.
3. Abbott BL (2003) ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol 21:115-130.
4. Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, et al. (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15:3574-3582.
5. Advani AS, Shadman M, Ali-Osman F, Barker A, Rybicki L, Kalaycio M, Sekeres MA, de Castro CM, Diehl LF, Moore JO, et al. (2010) A phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. Clin Lymphoma Myeloma Leuk 10:473-476.
6. Allen SL and Lundberg AS (2011) Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs 20:995-1003.
7. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, and Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398. (Pubitemid 29222564)
8. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, and Limtrakul P (2006) Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res 29:866-873. (Pubitemid 44808452)
9. Ascione A, Cianfriglia M, Dupuis ML, Mallano A, Sau A, Pellizzari Tregno F, Pezzola S, and Caccuri AM (2009) The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells. Cancer Chemother Pharmacol 64:419-424.
10. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, et al. (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224-1232. (Pubitemid 34864276)
11. Balatzenko G, Stoimenov A, Guenova M, Galabova I, Ganeva P, Hodjadjik D, and Toshkov S (2002) Application of reverse transcription polymerase chain reaction for analysis of multidrug resistance in patients with acute myeloblastic leukemia. J BUON 7:355-359. (Pubitemid 36582134)
12. Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Sałagacka A, and Mirowski M (2010) ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 25:1167-1176.
13. Baran Y, Gür B, Kaya P, Ural AU, Avcu F, and Gündüz U (2007) Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology 12:511-517. (Pubitemid 350048061)
14. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, et al. (2004) A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 10:4724-4733. (Pubitemid 38955523)
15. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, et al. (2006) Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 107:1315-1324. (Pubitemid 43242364)
16. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, Netter-Pinon G, Frenay M, Gousset C, Marié FN, et al. (2000) Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 11:1471-1476.
17. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, and Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896-7902. (Pubitemid 39587528)
18. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, and Legrand O (2005) MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11:7764-7772. (Pubitemid 41611620)
19. Blanchard F, Kinzie E, Wang Y, Duplomb L, Godard A, Held WA, Asch BB, and Baumann H (2002) FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins. Oncogene 21:6264-6277.
20. Brozek J, Bryl E, Płoszyńska A, Balcerska A, and Witkowski JM (2009) P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 31:493-499.
21. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Bladé J, and Orlowski RZ (2010) Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89:1133-1140.
22. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, and Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476.
23. Chai L, McLaren RP, Byrne A, Chuang WL, Huang Y, Dufault MR, Pacheco J, Madhiwalla S, Zhang X, Zhang M, et al. (2011) The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function. Int J Oncol 38:701-711.
24. Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, et al. (2008) Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 22:1576-1586.
25. Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, and Wulf GG (2009) ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica 94:1528-1536.
26. Chau M, Christensen JL, Ajami AM, and Capizzi RL (2008) Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 32:465-473. (Pubitemid 351295924)
27. Chen BA, Mao PP, Cheng J, Gao F, Xia GH, Xu WL, Shen HL, Ding JH, Gao C, Sun Q, et al. (2010) Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells. Int J Nanomedicine 5:437-444.
28. Cianfriglia M, Mallano A, Ascione A, and Dupuis ML (2010) Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-γ1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol 36:1513-1520.
29. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG, Russel FG, Shayo C, and Davio C (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286:6979-6988.
30. Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, and Tallman MS (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116:4077-4085.
31. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, and Clark RE (2005) hOCT 1 and resistance to imatinib. Blood 106:1133-1134.
32. Cuestas ML, Sosnik A, and Mathet VL (2011) Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines. Mol Pharm 8:1152-1164.
33. Dai CL, Liang YJ, Chen LM, Zhang X, Deng WJ, Su XD, Shi Z, Wu CP, Ashby CR Jr, Akiyama S, et al. (2009) Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochem Pharmacol 78:355-364.
34. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, et al. (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68:7905-7914.
35. Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A, Cavallin M, and Fanin R (2006) The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91:825-828. (Pubitemid 44014553)
36. Damiani D, Tiribelli M, Michelutti A, Geromin A, Cavallin M, Fabbro D, Pianta A, Malagola M, Damante G, Russo D, et al. (2010) Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res 34:942-945.
37. Dantzig AH, de Alwis DP, and Burgess M (2003) Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55:133-150. (Pubitemid 36078455)
38. + chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23:1999-2006.
39. Dean M, Rzhetsky A, and Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166. (Pubitemid 32677289)
40. Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, et al. (2004) Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anticancer Drugs 15:861-869. (Pubitemid 39482926)
41. Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, et al. (2011) The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 6:e19329.
42. Dizdarevic S and Peters AM (2011) Imaging of multidrug resistance in cancer. Cancer Imaging 11:1-8.
43. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, and Bates SE (2010) Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38:1371-1380.
44. Drain S, Catherwood MA, and Alexander HD (2010) Multidrug resistance in the chronic lymphoproliferative disorders. Leuk Lymphoma 51:1793-1804.
45. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, and Mahon FX (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:2024-2027.
46. Efferth T, Sauerbrey A, Steinbach D, Gebhart E, Drexler HG, Miyachi H, Chitambar CR, Becker CM, Zintl F, and Humeny A (2003) Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol 23:509-517.
47. El-Readi MZ, Hamdan D, Farrag N, El-Shazly A, and Wink M (2010) Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur J Pharmacol 626:139-145.
48. El-Sharnouby JA, Abou El-Enein AM, El Ghannam DM, El-Shanshory MR, Hagag AA, Yahia S, and Elashry R (2010) Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia. J Oncol Pharm Pract 16:179-188.
49. Elsby R, Smith V, Fox L, Stresser D, Butters C, Sharma P, and Surry DD (2011) Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica 41:764-783.
50. Engler JR, Hughes TP, and White DL (2011) OCT-1 as a determinant of response to antileukemic treatment. Clin Pharmacol Ther 89:608-611.
51. Erba HP (2007) Prognostic factors in elderly patients with AML and the implications for treatment. Hematology Am Soc Hematol Educ Program 420-428.
52. Fazlina N, Maha A, Zarina AL, Hamidah A, Zulkifli SZ, Cheong SK, Ainoon O, Jamal R, and Hamidah NH (2008) Assessment of P-gp and MRP1 activities using MultiDrugQuant assay kit: a preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients. Malays J Pathol 30:87-93.
53. Fox E and Bates SE (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7:447-459. (Pubitemid 46681800)
54. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, and Frank MH (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320-4333. (Pubitemid 40775671)
55. Gao A, Liang H, Wang X, Zhang X, Jing M, Zhang J, Yan Y, and Xiang W (2011) Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro. Eur J Pharmacol 659:108-113.
56. Gardner ER, Smith NF, Figg WD, and Sparreboom A (2009) Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. J Exp Clin Cancer Res 28:99.
57. Genoux-Bastide E, Lorendeau D, Nicolle E, Yahiaoui S, Magnard S, Di Pietro A, Baubichon-Cortay H, and Boumendjel A (2011) Identification of xanthones as selective killers of cancer cells overexpressing the ABC transporter MRP1. ChemMedChem 6:1478-1484.
58. Germano S and O'Driscoll L (2009) Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine. Curr Cancer Drug Targets 9:398-418.
59. Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG, Ethell M, McCullough H, Burgess M, Mehta AB, et al. (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89:782-790. (Pubitemid 38981338)
60. Globisch C, Pajeva IK, and Wiese M (2006) Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators. Bioorg Med Chem 14:1588-1598. (Pubitemid 43120295)
61. Goldman B (2003) Multidrug resistance: can new drugs help chemotherapy score against cancer? J Natl Cancer Inst 95:255-257.
62. Goldsborough AS, Handley MD, Dulcey AE, Pluchino KM, Kannan P, Brimacombe KR, Hall MD, Griffiths G, and Gottesman MM (2011) Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem 54:4987-4997.
63. Gonzalez-Haba E, García MI, Cortejoso L, López-Lillo C, Barrueco N, García-Alfonso P, Alvarez S, Jiménez JL, Martín ML, Muñóz-Fernández MA, et al. (2010) ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 11:1715-1723.
64. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, et al. (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22:1078-1086. (Pubitemid 41095041)
65. Guenova ML, Balatzenko GN, Nikolova VR, Spassov BV, and Konstantinov SM (2010) An anti-apoptotic pattern correlates with multidrug resistance in acute myeloid leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-2, survivin and MDR1 gene. Hematology 15:135-143.
66. Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, et al. (2011) Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J 13:357-364.
67. Hall MD, Handley MD, and Gottesman MM (2009) Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 30:546-556.
68. Hamidovic A, Hahn K, and Kolesar J (2010) Clinical significance of ABCB1 genotyping in oncology. J Oncol Pharm Pract 16:39-44.
69. Hampras SS, Sucheston L, Weiss J, Baer MR, Zirpoli G, Singh PK, Wetzler M, Chennamaneni R, Blanco JG, Ford L, et al. (2010) Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemia. Int J Mol Epidemiol Genet 1:201-207.
70. Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lübbert M, Peschel C, Keller U, and Licht T (2009) Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 15:3705-3715.
71. Hipfner DR, Deeley RG, and Cole SP (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461:359-376.
72. Ho MM, Hogge DE, and Ling V (2008) MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol 36:433-442.
73. Holló Z, Homolya L, Davis CW, and Sarkadi B (1994) Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191:384-388. (Pubitemid 24183562)
74. Homolya L, Holló M, Müller M, Mechetner EB, and Sarkadi B (1996) A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer 73:849-855. (Pubitemid 26111312)
75. Hu M, Liu Y, Deng C, Han R, Jia Y, Liu S, Jiang Z, Cao X, He L, and Zhang Q (2011) Enhanced invasiveness in multidrug resistant leukemic cells is associated with overexpression of P-glycoprotein and cellular inhibitor of apoptosis protein. Leuk Lymphoma 52:1302-1311.
76. Hubensack M, Müller C, Höcherl P, Fellner S, Spruss T, Bernhardt G, and Buschauer A (2008) Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134:597-607. (Pubitemid 351422612)
77. Huh HJ, Park CJ, Jang S, Seo EJ, Chi HS, Lee JH, Lee KH, Seo JJ, Moon HN, and Ghim T (2006) Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 21:253-258. (Pubitemid 43763997)
78. Hunter HM, Pallis M, Seedhouse CH, Grundy M, Gray C, and Russell NH (2004) The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Haematol 127:26-33. (Pubitemid 39331103)
79. Hur EH, Lee JH, Lee MJ, Choi SJ, Lee JH, Kang MJ, Seol M, Jang YE, Lee HJ, Kang IS, et al. (2008) C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. Leuk Res 32:1601-1604.
80. Ikeda R, Vermeulen LC, Lau E, Jiang Z, Sachidanandam K, Yamada K, and Kolesar JM (2011) Isolation and characterization of gemcitabine-resistant human nonsmall cell lung cancer A549 cells. Int J Oncol 38:513-519.
81. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G, and Schaich M (2002) MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-4962. (Pubitemid 34984419)
82. Jamroziak K, Balcerczak E, Cebula B, Janus A, Mirowski M, and Robak T (2006) No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells. Ther Drug Monit 28:707-711. (Pubitemid 44564075)
83. Jamroziak K, Balcerczak E, Cebula B, Kowalczyk M, Panczyk M, Janus A, Smolewski P, Mirowski M, and Robak T (2005) Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep 57:882-888.
84. Jamroziak K, Młynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, and Robak T (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72:314-321. (Pubitemid 38520728)
85. Kang H, Fisher MH, Xu D, Miyamoto YJ, Marchand A, Van Aerschot A, Herdewijn P, and Juliano RL (2004) Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res 32:4411-4419. (Pubitemid 39232313)
86. Kanintronkul Y, Worayuthakarn R, Thasana N, Winayanuwattikun P, Pattanapanyasat K, Surarit R, Ruchirawat S, and Svasti J (2011) Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones. Anticancer Res 31:921-927.
87. Kartner N, Riordan JR, and Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288. (Pubitemid 13005502)
88. 18F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters. Bioorg Med Chem 19:861-870.
89. Kaya P, Gündüz U, Arpaci F, Ural AU, and Guran S (2005) Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol 80:26-34. (Pubitemid 41254264)
90. Kim DH, Lee NY, Kim JG, Sohn SK, Won DI, Suh JS, Lee GS, Chae SC, and Lee KB (2005) Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia. Leuk Lymphoma 46:63-70.
91. Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, and Lee KB (2006) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118:2195-2201.
92. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, and Lipton JH (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15:4750-4758.
93. Kim H, Kim SN, Park YS, Kim NH, Han JW, Lee HY, and Kim YK (2011) HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. Int J Oncol 38:807-812.
94. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, et al. (2004) Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22:4290-4301. (Pubitemid 41185150)
95. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, et al. (2010) P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B Study 19808. Blood 116:1413-1421.
96. Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T, Koliouskas D, and Athanassiadou F (2007) Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 86:166-173. (Pubitemid 47425197)
97. Kowalski P, Stein U, Scheffer GL, and Lage H (2002) Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 9:579-586. (Pubitemid 34734422)
98. Kweon SH, Song JH, and Kim TS (2010) Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395:104-110.
99. Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, and Schinkel AH (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15:2344-2351.
100. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, and Fauchet R (1995) Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 9:1549-1555.
101. Laupeze B, Amiot L, Drenou B, Bernard M, Branger B, Grosset JM, Lamy T, Fauchet R, and Fardel O (2002) High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 116:834-838. (Pubitemid 34227003)
102. Le Vee M, Jouan E, Stieger B, Lecureur V, and Fardel O (2011) Regulation of drug transporter expression by oncostatin M in human hepatocytes. Biochem Pharmacol 82:304-311.
103. Legrand O, Perrot JY, Simonin G, Baudard M, and Marie JP (2001) JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 97:502-508. (Pubitemid 32060337)
104. Legrand O, Simonin G, Perrot JY, Zittoun R, and Marie JP (1998) Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91:4480-4488. (Pubitemid 28270294)
105. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, et al. (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood 94:1086-1099. (Pubitemid 29361842)
106. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, and Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323-3329.
107. Leschziner GD, Andrew T, Pirmohamed M, and Johnson MR (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7:154-179. (Pubitemid 46794925)
108. Li GY, Liu JZ, Zhang B, Wang LX, Wang CB, and Chen SG (2009) Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Biomed Pharmacother 63:566-570.
109. Li R, Wu R, Zhao L, Wu M, Yang L, and Zou H (2010) P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 4:1399-1408.
110. Liang GW, Lu WL, Wu JW, Zhao JH, Hong HY, Long C, Li T, Zhang YT, Zhang H, Wang JC, et al. (2008) Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundam Clin Pharmacol 22:429-437.
111. Lim MN, Lau NS, Chang KM, Leong CF, and Zakaria Z (2007) Modulating multidrug resistance gene in leukaemia cells by short interfering RNA. Singapore Med J 48:932-938. (Pubitemid 351235282)
112. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, et al. (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212-3220.
113. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, et al. (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87:2464-2469. (Pubitemid 26086891)
114. Mahjoubi F, Akbari S, Montazeri M, and Moshyri F (2008) MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients. Genet Mol Res 7:1369-1374.
115. Maraldi T, Bertacchini J, Benincasa M, Guida M, De Pol A, Liotta LA, Petricoin E, Cocco L, and Marmiroli S (2011) Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. Int J Oncol 38:427-435.
116. Marie JP, Zittoun R, and Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586-592.
117. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, and Callaghan R (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128:403-411. (Pubitemid 29458600)
118. Mbuna J, Kaneta T, and Imasaka T (2011) Rapid determination of multidrug resistance-associated protein in cancer cells by capillary electrophoresis immunoassay. J Chromatogr A 1218:3923-3927.
119. Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, and Eckhardt SG (2007) The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines. Leukemia 21:739-746. (Pubitemid 46444558)
120. Merkel TJ and DeSimone JM (2011) Dodging drug-resistant cancer with diamonds. Sci Transl Med 3:73ps8.
121. Minematsu T and Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10:531-539.
122. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, and Charlton P (2001) In vitro and in vivo reversal of P-glycoproteinmediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749-758. (Pubitemid 32128642)
123. Moitra K, Lou H, and Dean M (2011) Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89:491-502.
124. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, et al. (2006) Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107:4871-4879. (Pubitemid 43882640)
125. Müller P, Asher N, Heled M, Cohen SB, Risch A, and Rund D (2008) Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. Leuk Res 32:919-929.
126. Nadali F, Pourfathollah AA, Alimoghaddam K, Nikougoftar M, Rostami S, Dizaji A, Azizi E, Zomorodipour A, and Ghavamzadeh A (2007) Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells. Hematology 12:393-401. (Pubitemid 47487847)
127. Nagai S, Takenaka K, Nachagari D, Rose C, Domoney K, Sun D, Sparreboom A, and Schuetz JD (2011) Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 71:1781-1791.
128. Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, and Ross DD (2003) Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 9:3320-3328. (Pubitemid 37082726)
129. Napper JM and Sollars VE (2010) 17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells. Leuk Res 34:1493-1500.
130. Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, et al. (2010) Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol 66:585-596.
131. Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, and Qian SX (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28:265-269.
132. Nobili S, Landini I, Mazzei T, and Mini E (2011) Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev doi:10.1002/med.20239.
133. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, et al. (2010) Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 54:694-702.
134. Ohnuma S, Chufan E, Nandigama K, Jenkins LM, Durell SR, Appella E, Sauna ZE, and Ambudkar SV (2011) Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5′-fluorosulfonylbenzoyl 5′-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sites. Biochemistry 50:3724-3735.
135. Paller CJ and Antonarakis ES (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 5:117-124.
136. Pallis M, Turzanski J, Higashi Y, and Russell N (2002) P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 43:1221-1228. (Pubitemid 34537966)
137. Patel KJ and Tannock IF (2009) The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer 9:356.
138. Patil Y, Sadhukha T, Ma L, and Panyam J (2009) Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136:21-29.
139. Pein F, Pinkerton R, Berthaud P, Pritchard-Jones K, Dick G, and Vassal G (2007) Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours. Eur J Cancer 43:2074-2081. (Pubitemid 47380364)
140. Pereira E, Borrel MN, Fiallo M, and Garnier-Suillerot A (1994) Non-competitive inhibition of P-glycoprotein-associated efflux of THP-Adriamycin by verapamil in living K562 leukemia cells. Biochim Biophys Acta 1225:209-216. (Pubitemid 24033283)
141. Piwnica-Worms D and Sharma V (2010) Probing multidrug resistance P-glycoprotein transporter activity with SPECT radiopharmaceuticals. Curr Top Med Chem 10:1834-1845.
142. Plasschaert SL, de Bont ES, Boezen M, vander Kolk DM, Daenen SM, Faber KN, Kamps WA, de Vries EG, and Vellenga E (2005) Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 11:8661-8668. (Pubitemid 43005914)
143. Prenkert M, Uggla B, Tina E, Tidefelt U, and Strid H (2009) Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells. Anticancer Res 29:4071-4076.
144. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, and Reinhardt D (2005) Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 312:346-354. (Pubitemid 40096488)
145. - cells in acute myeloid leukemia. Clin Cancer Res 11:2436-2444.
146. Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D, and Rajappa S (2010) Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev 11:1063-1066.
147. Raub TJ (2006) P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 3:3-25.
148. Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, and Bosia A (2011) Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 8:683-700.
149. Robey RW, Lin B, Qiu J, Chan LL, and Bates SE (2011) Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods 63:217-222.
150. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T, and SHG AML96 Study Group (2005) MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128:324-332. (Pubitemid 40216154)
151. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, and Scheper RJ (1995) The drug resistance-related protein LRP is the human major vault protein. Nat Med 1:578-582.
152. Seo T, Urasaki Y, and Ueda T (2007) Establishment of an arsenic trioxideresistant human leukemia cell line that shows multidrug resistance. Int J Hematol 85:26-31. (Pubitemid 46193286)
153. Shao SL, Zhang WW, Li XY, Zhang ZZ, Yun DZ, Fu B, and Zuo MX (2010) Reversal of MDR1 gene-dependent multidrug resistance in HL60/HT9 cells using short hairpin RNA expression vectors. Cancer Biother Radiopharm 25:171-177.
154. Shepard RL, Cao J, Starling JJ, and Dantzig AH (2003) Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103:121-125. (Pubitemid 35424215)
155. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, et al. (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67:11012-11020. (Pubitemid 350145931)
156. Shi Z, Tiwari AK, Patel AS, Fu LW, and Chen ZS (2011a) Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res 71:3735-3738.
157. Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, et al. (2009) Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 77:781-793.
158. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, et al. (2011b) Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 71:3029-3041.
159. - cells in childhood AML. Ann Hematol 87:353-360.
160. Sivapackiam J, Harpstrite SE, Prior JL, Gu H, Rath NP, and Sharma V (2010) Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport. Dalton Trans 39:5842-5850.
161. Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Boezeman J, Minderman H, and de Witte TM (1999) Idarubicin DNA intercalation is reduced by MRP1 and not Pgp. Leukemia 13:1390-1398. (Pubitemid 29429766)
162. Solary E, Drenou B, Campos L, de Crémoux P, Mugneret F, Moreau P, Lioure B, Falkenrodt A, Witz B, Bernard M, et al. (2003) Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 102:1202-1210. (Pubitemid 36988023)
163. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, and Efferth T (2006) ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 12:4357-4363.
164. Steinbach D and Legrand O (2007) ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the hydra? Leukemia 21:1172-1176. (Pubitemid 46831804)
165. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, and Sauerbrey A (2003a) Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 9:1083-1086. (Pubitemid 36323715)
166. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, and Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447.
167. Steinbach D, Wittig S, Cario G, Viehmann S, Mueller A, Gruhn B, Haefer R, Zintl F, and Sauerbrey A (2003b) The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 102:4493-4498.
168. Suárez L, Vidriales MB, Moreno MJ, López A, García-Laraña J, Pérez-López C, Tormo M, Lavilla E, López-Berges MC, de Santiago M, et al. (2005) Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica 90:54-59. (Pubitemid 40193754)
169. Svirnovski AI, Shman TV, Serhiyenka TF, Savitski VP, Smolnikova VV, and Fedasenka UU (2009) ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology 14:204-212.
170. Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6:129-137. (Pubitemid 39485685)
171. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234. (Pubitemid 43336035)
172. Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G, Mecucci C, Tedeschi A, Fioritoni G, Ferrara F, et al. (2002) MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 100:974-981. (Pubitemid 34832626)
173. Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, and Li D (2011) Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 117:744-751.
174. Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T, Morjani H, Legrand O, and Marie JP (2008) Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 8:51.
175. Tiribelli M, Geromin A, Michelutti A, Cavallin M, Pianta A, Fabbro D, Russo D, Damante G, Fanin R, and Damiani D (2011) Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Cancer 117:2156-2162.
176. Tran VH, Marks D, Duke RK, Bebawy M, Duke CC, and Roufogalis BD (2011) Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr Cancer 63:435-443.
177. Trnková Z, Bedrlíková R, Marková J, Michalová K, Stöckbauer P, and Schwarz J (2007) Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia. Neoplasma 54:383-390.
178. Trompier D, Chang XB, Barattin R, du Moulinet D'Hardemare A, Di Pietro A, and Baubichon-Cortay H (2004) Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64:4950-4956. (Pubitemid 38924542)
179. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, Smith AG, and Gant TW (2001) Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20:1300-1306. (Pubitemid 32269935)
180. Uggla B, Ståhl E, Wågsäter D, Paul C, Karlsson MG, Sirsjö A, and Tidefelt U (2005) BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 29:141-146. (Pubitemid 39647507)
181. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, Vellenga E, Ossenkoppele GJ, Löwenberg B, and Sonneveld P (2007) CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329-337. (Pubitemid 46477296)
182. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, van der Holt B, Vossebeld PJ, Pieters R, and Sonneveld P (2001) MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97:3605-3611.
183. van der Holt B, Löwenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GE, Ferrant A, Crump M, et al. (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106:2646-2654. (Pubitemid 41510736)
184. van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ, Löwenberg B, and Sonneveld P (2006) ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 80:427-439. (Pubitemid 44767876)
185. van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, and Vellenga E (2000) P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 6:3205-3214. (Pubitemid 30637749)
186. van Zuylen L, Nooter K, Sparreboom A, and Verweij J (2000) Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs 18:205-220. (Pubitemid 30599141)
187. Venditti A, Del Poeta G, Maurillo L, Buccisano F, Del Principe MI, Mazzone C, Tamburini A, Cox C, Panetta P, Neri B, et al. (2004) Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica 89:934-939. (Pubitemid 39049901)
188. Versiani MA, Diyabalanage T, Ratnayake R, Henrich CJ, Bates SE, McMahon JB, and Gustafson KR (2011) Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2. J Nat Prod 74:262-266.
189. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, and Linenberger ML (2003) Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102:1466-1473. (Pubitemid 36988058)
190. Wang J, Tai LS, Tzang CH, Fong WF, Guan XY, and Yang M (2008) 1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells. Oncol Rep 19:1155-1164.
191. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, Milpied N, Janvier M, Guerci A, Rochant H, et al. (1999) Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP): updated results of a randomized study. Adv Exp Med Biol 457:35-46. (Pubitemid 129735296)
192. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, and Hughes T (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064-4072. (Pubitemid 350248463)
193. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, and Hughes TP (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697-704. (Pubitemid 44061372)
194. Wilson BJ, Schatton T, Zhan Q, Gasser M, Ma J, Saab KR, Schanche R, Waaga-Gasser AM, Gold JS, Huang Q, et al. (2011) ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res 71:5307-5316.
195. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, et al. (2006) Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108:685-696. (Pubitemid 44061371)
196. Wu CP, Calcagno AM, and Ambudkar SV (2008) Reversal of ABC drug transportermediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 1:93-105.
197. Wuchter C, Leonid K, Ruppert V, Schrappe M, Büchner T, Schoch C, Haferlach T, Harbott J, Ratei R, Dörken B, et al. (2000) Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85:711-721. (Pubitemid 30617105)
198. Xiang QF, Wang F, Su XD, Liang YJ, Zheng LS, Mi YJ, Chen WQ, and Fu LW (2011) Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell Oncol (Dordr) 34:33-44.
199. Xu D, Fang L, Zhu Q, Hu Y, He Q, and Yang B (2008) Antimultidrug- resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells. Pharmazie 63:528-533.
200. Xu D, Ye D, Fisher M, and Juliano RL (2002) Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther 302:963-971. (Pubitemid 34920217)
201. Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M, et al. (2011) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104:707-713.
202. Yamazaki R, Nishiyama Y, Furuta T, Hatano H, Igarashi Y, Asakawa N, Kodaira H, Takahashi H, Aiyama R, Matsuzaki T, et al. (2011) Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther 10:1252-1263.
203. Yang K, Wu J, and Li X (2008) Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2:137-146.
204. Yang YL, Lin DT, Chang SK, Lin SR, Lin SW, Chiou RJ, Yen CT, Lin KH, Jou ST, Lu MY, et al. (2010) Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 54:206-211.
205. Ye CG, Wu WK, Yeung JH, Li HT, Li ZJ, Wong CC, Ren SX, Zhang L, Fung KP, and Cho CH (2011) Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett 304:90-96.
206. Zhang D and Fan D (2010) New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 6:527-537.
207. Zhang H, Jiang H, Sun F, Wang H, Zhao J, Chen B, and Wang X (2011a) Rapid diagnosis of multidrug resistance in cancer by electrochemical sensor based on carbon nanotubes-drug supramolecular nanocomposites. Biosens Bioelectron 26:3361-3366.
208. Zhang P, Ling G, Sun J, Zhang T, Yuan Y, Sun Y, Wang Z, and He Z (2011b) Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux. Biomaterials 32:5524-5533.
209. Zhang X, Xiao W, Wang L, Tian Z, and Zhang J (2011c) Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS One 6:e20965.
210. Zhang YY, Xie KM, Yang GQ, Mu HJ, Yin Y, Zhang B, and Xie P (2011d) The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line. Int J Hematol 93:361-367.
211. Zheng Z, Aojula H, and Clarke D (2010) Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide. J Drug Target 18:477-487.